Commitments and Contingencies - Additional Information (Detail)							1 Months Ended		3 Months Ended					12 Months Ended
	Dec. 15, 2021 USD ($) shares	Jun. 18, 2021 USD ($)	Mar. 15, 2021 USD ($)	Apr. 01, 2020 USD ($)	Jan. 01, 2019 USD ($)	May 08, 2017 USD ($)	Apr. 30, 2020	May 31, 2017 USD ($)	Dec. 31, 2022 USD ($) $ / €	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) $ / SFr	Mar. 31, 2020 USD ($) $ / SFr	Mar. 31, 2020 CHF (SFr)	Dec. 31, 2022 USD ($) $ / €	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 USD ($) $ / SFr	Dec. 31, 2021 CHF (SFr) $ / SFr	Dec. 31, 2020 USD ($)	Dec. 31, 2022 CHF (SFr) $ / €
Loss Contingencies [Line Items]
Amount committed in investment														$ 36,200,000
Net cash payments for investment														2,000,000.0
Other Long-Term Assets [Member]
Loss Contingencies [Line Items]
Amount committed in investment														27,000,000.0
Cost of Goods Sold [Member]
Loss Contingencies [Line Items]
Royalty and earnout expense														338,500,000			$ 289,700,000		$ 169,300,000
Other Income (Expense), Net [Member]
Loss Contingencies [Line Items]
Investment income														2,000,000.0			700,000
TEPEZZA [Member]
Loss Contingencies [Line Items]
Upfront cash payment																			30,000,000.0
Maximum payment to be made upon attainment of milestones																			$ 160,000,000.0
River Vision [Member]
Loss Contingencies [Line Items]
Milestone Payment								$ 325,000,000.0	$ 325,000,000.0					$ 325,000,000.0
Percentage of net sales in earn-out payment														3.00%	3.00%	3.00%
Net sales minimum limit for royal payment														$ 300,000,000.0
Upfront cash payments						$ 150,300,000
River Vision [Member] | FDA Approval [Member]
Loss Contingencies [Line Items]
Milestone Payment								100,000,000.0
River Vision [Member] | U.S. Food and Drug Administration (FDA) Approval [Member]
Loss Contingencies [Line Items]
Milestone Payment									100,000,000.0			$ 100,000,000.0		100,000,000.0
Alpine [Member]
Loss Contingencies [Line Items]
Upfront cash payments										$ 25,000,000.0	$ 15,000,000.0
Maximum amount eligible to receive per program	$ 381,000,000.0
Total future success-based payments related to development, regulatory and commercial milestones	$ 1,520,000,000
Alpine [Member] | Upfront Payment [Member]
Loss Contingencies [Line Items]
Business acquisition, costs																	$ 25,000,000.0
Alpine [Member] | Private Placement [Member]
Loss Contingencies [Line Items]
Purchase of common stock shares | shares	951,980
Curzion Pharmaceuticals Inc [Member]
Loss Contingencies [Line Items]
Upfront cash payments				$ 45,000,000.0
Additional payment to be made upon attainment of milestones				$ 15,000,000.0
Xeris Pharmaceuticals, Inc [Member]
Loss Contingencies [Line Items]
Milestone incurred														6,000,000.0
Milestone payment receive upon earlier exercise of option.														6,000.0
Xeris Pharmaceuticals, Inc [Member] | Upfront Payment [Member]
Loss Contingencies [Line Items]
Business acquisition, costs														2,750,000
Q32 Bio Inc [Member]
Loss Contingencies [Line Items]
Milestone incurred														645,000,000.0
Q32 Bio Inc [Member] | Upfront Payment [Member]
Loss Contingencies [Line Items]
Business acquisition, costs														15,000,000.0
Q32 Bio Inc [Member] | Milestone-based Development Funding [Member]
Loss Contingencies [Line Items]
Business acquisition, costs														17,500,000
Maximum [Member] | Q32 Bio Inc [Member] | Additional Milestone-based Development Funding [Member]
Loss Contingencies [Line Items]
Business acquisition, costs														22,500,000
Teprotumumab [Member] | River Vision [Member] | Net Sales Thresholds [Member]
Loss Contingencies [Line Items]
Milestone Payment								$ 225,000,000.0	225,000,000.0					225,000,000.0
PROCYSBI Developed Technology [Member] | Amended and Restated License Agreement [Member]
Loss Contingencies [Line Items]
Minimum annual royalty obligations									100,000					100,000
Aggregate development milestone payments amount for orphan indication														300,000
Aggregate regulatory milestone payments amount for orphan indication														1,800,000
Aggregate development milestone payments amount for non-orphan indication														800,000
Aggregate regulatory milestone payments amount for non-orphan indication														3,500,000
UPLIZNA [Member] | Viela Bio [Member]
Loss Contingencies [Line Items]
Net sales minimum limit for royal payment			$ 500,000,000.0
UPLIZNA [Member] | Maximum [Member] | Viela Bio [Member]
Loss Contingencies [Line Items]
Milestone incurred			$ 30,000,000.0
BUPHENYL, DUEXIS, PENNSAID 2%, PROCYSBI, QUINSAIR, RAVICTI, RAYOS, UPLIZNA and VIMOVO [Member]
Loss Contingencies [Line Items]
Purchase and other commitments outstanding purchase orders									$ 17,400,000					17,400,000
AGC Biologics A/S [Member] | PROCYSBI API [Member]
Loss Contingencies [Line Items]
Minimum binding purchase commitment														$ 77,600,000		€ 72,800,000
Currency exchange rate | $ / €									10,660.0000					10,660.0000						10,660.0000
Patheon Pharmaceuticals Inc. [Member] | TEPEZZA Drug Product [Member]
Loss Contingencies [Line Items]
Minimum binding purchase commitment														$ 7,400,000		€ 7,000.0
Currency exchange rate | $ / €									10,660.0000					10,660.0000						10,660.0000
Catalent [Member] | TEPEZZA Drug Product [Member]
Loss Contingencies [Line Items]
Minimum binding purchase commitment														$ 6,000,000.0
Bio-Technology General (Israel) Ltd [Member] | KRYSTEXXA Developed Technology [Member]
Loss Contingencies [Line Items]
Minimum binding purchase commitment														$ 1,800,000
Bio-Technology General (Israel) Ltd [Member] | KRYSTEXXA Developed Technology [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Purchase obligation percentage														80.00%	80.00%	80.00%
Boehringer Ingelheim [Member] | ACTIMMUNE Developed Technology [Member]
Loss Contingencies [Line Items]
Minimum binding purchase commitment														$ 6,300,000		€ 5,900,000
Currency exchange rate | $ / €									10,660.0000					10,660.0000						10,660.0000
S R One And Lundbeckfond | River Vision [Member]
Loss Contingencies [Line Items]
Percentage of net sales in earn-out payment								3.00%									0.893%	0.893%
Net sales minimum limit for royal payment								$ 300,000,000.0									$ 300,000,000.0
Percentage of right to receive payments							35.66%
Percentage of remaining net obligations payments							70.25%
Milestone incurred																	$ 67,000,000.0
Roche [Member]
Loss Contingencies [Line Items]
Currency exchange rate									10,823.0000			1.0382		10,823.0000						10,823.0000
Milestone incurred												$ 5,200,000	SFr 5,000,000.0	$ 46,500,000	SFr 43,000,000.0
Roche [Member] | U.S. Food and Drug Administration (FDA) Approval [Member]
Loss Contingencies [Line Items]
Currency exchange rate | $ / SFr											1.0382						1.0382	1.0382
Milestone incurred												$ 5,200,000	SFr 5,000,000.0
Roche [Member] | TEPEZZA [Member]
Loss Contingencies [Line Items]
Currency exchange rate | $ / SFr											11,228						11,228	11,228
Milestone incurred																	$ 56,100,000	SFr 50,000,000.0
Roche [Member] | River Vision [Member]
Loss Contingencies [Line Items]
Milestone Payment | SFr																				SFr 103,000,000.0
Roche [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Percentage of net sales in earn-out payment														9.00%	9.00%	9.00%
Roche [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Percentage of net sales in earn-out payment														12.00%	12.00%	12.00%
Duke [Member] | Minimum [Member] | License Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales revenue														5.00%	5.00%	5.00%
Duke [Member] | Maximum [Member] | License Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales revenue														15.00%	15.00%	15.00%
Duke [Member] | KRYSTEXXA Developed Technology [Member] | Minimum [Member] | License Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales revenue														5.00%	5.00%	5.00%
Duke [Member] | KRYSTEXXA Developed Technology [Member] | Maximum [Member] | License Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales revenue														15.00%	15.00%	15.00%
MVP [ Member] | Minimum [Member] | License Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales revenue														5.00%	5.00%	5.00%
MVP [ Member] | Maximum [Member] | License Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales revenue														15.00%	15.00%	15.00%
MVP [ Member] | KRYSTEXXA Developed Technology [Member] | Minimum [Member] | License Agreement [Member] | Non-US [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales revenue														5.00%	5.00%	5.00%
MVP [ Member] | KRYSTEXXA Developed Technology [Member] | Maximum [Member] | License Agreement [Member] | Non-US [Member]
Loss Contingencies [Line Items]
Percentage of royalty on net sales revenue														15.00%	15.00%	15.00%
Vectura [Member] | RAYOS [Member]
Loss Contingencies [Line Items]
Minimum annual royalty obligations					$ 8,000,000.0
Royalty commitments expiration date					Dec. 31, 2022
TEPEZZA And KRYSTEXXA [Member]
Loss Contingencies [Line Items]
Advertising commitments														$ 71,300,000
HZN457 [Member]
Loss Contingencies [Line Items]
Upfront cash payment		$ 40,000,000.0
Development milestone recognized									$ 15,000.0
HZN457 [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Maximum payment to be made upon attainment of milestones		$ 660,000,000.0